Frequently Asked Questions
The market is segmented based on , By Type (Inorganic Nanoparticles, Organic Nanoparticles), Agent Type (Diagnostic Agents, Therapeutic Agents, Drug Delivery Agents), Mechanism (Targeting Tumor Cells, Nanocarrier - Drug Complex, Drug Release Systems), Cancer Type (Breast Cancer, Pancreatic Cancer, Brain Cancer, Lung Cancer, Others), Imaging Technique (Positron Emission Tomography, Single Photon Emitted Tomography, Magnetic Resonance Imaging (MRI)), Phase (Research, Preclinical, Phase-I, Phase-I/II, Phase-II, Phase-III) – Industry Trends and Forecast to 2030.
.
The Global Cancer Nanomedicine Market size was valued at USD 180.00 USD Billion in 2022.
The Global Cancer Nanomedicine Market is projected to grow at a CAGR of 12% during the forecast period of 2023 to 2030.
The major players operating in the market include Alnylam Pharmaceuticals, Amgen , Arrowhead Pharmaceuticals, AstraZeneca, Cadila Pharmaceuticals, CELGENE CORPORATION, Celsion Corporation, Genzyme, Merck & Co., Nippon Kayaku Co., Nanobiotix, Pfizer , F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, General Electric, Johnson & Johnson Services, Teva Pharmaceutical Industries , Gilead Sciences, Novartis AG.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
